Who Paid My Doc
Kori Williams
Nurse Practitioner, Primary Care Bakersfield, CA Nurse Practitioner
NPI 1013457969 CMS profile 10544763
8307 Brimhall Rd, Ste 1707, Bakersfield, CA 93312
General payments
$11,525
Research payments
$0
Ownership & investment interest
$0
Through program year 2025, Kori Williams of Bakersfield, CA is reported in the CMS Open Payments database as having received $11,525 across 456 general payments and $0 in research payments paid to them.
No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.
General payments for this record sit in the 98th percentile of Nurse Practitioner, Primary Care profiles with reported payments. Percentile describes the distribution, not the conduct.
By program year
5 rows| Year | Kind | Relative to this record's peak year | Amount | Records |
|---|---|---|---|---|
| 2025 | General | $3,830 | 146 | |
| 2024 | General | $3,549 | 105 | |
| 2023 | General | $2,206 | 100 | |
| 2022 | General | $1,248 | 58 | |
| 2021 | General | $691 | 47 |
Beside peers
- Kori Williams
- Nurse Practitioner, Primary Care median
- Middle half of Nurse Practitioner, Primary Care
- National median
In program year 2025, general payments to Kori Williams were reported at $3,830. Among 4,814 Nurse Practitioner, Primary Care profiles paid that year, the median was $169 and the middle half received between $51 and $499.
Show as a table
| Year | Kori Williams | Nurse Practitioner, Primary Care median | Middle half | National median |
|---|---|---|---|---|
| 2019 | $0 | — | — | $163 |
| 2020 | $0 | — | — | $114 |
| 2021 | $691 | $137 | $39–$445 | $132 |
| 2022 | $1,248 | $139 | $44–$421 | $149 |
| 2023 | $2,206 | $163 | $53–$481 | $160 |
| 2024 | $3,549 | $176 | $54–$511 | $164 |
| 2025 | $3,830 | $169 | $51–$499 | $169 |
Breakdown
A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.
Prescribing to Medicare patients
Part D · data year 2024 · 57 drugsPart D claims
3,915
Drug cost
$2,045,663
Branded share of claims
62.5%
| Drug | Type | Relative to their largest | Claims | Drug cost |
|---|---|---|---|---|
| Ozempic Semaglutide | Brand | 585 | $576,612 | |
| Tymlos Abaloparatide | Brand | 75 | $249,766 | |
| Jardiance Empagliflozin | Brand | 217 | $196,320 | |
| Trulicity Dulaglutide | Brand | 184 | $190,018 | |
| Mounjaro Tirzepatide | Brand | 135 | $147,248 | |
| Farxiga Dapagliflozin Propanediol | Brand | 120 | $108,761 | |
| Forteo Teriparatide | Brand | 25 | $108,207 | |
| Prolia Denosumab | Brand | 42 | $70,806 | |
| Tresiba Flextouch U-200 Insulin Degludec | Brand | 52 | $36,532 | |
| Rybelsus Semaglutide | Brand | 27 | $34,469 |
The 10 drugs with the highest cost, of 57 counted.
Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.
Payments and prescribing
First 5 of 19 products · payments 2024Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.
| Product | Paid by | Related payments | Part D claims | Part B services |
|---|---|---|---|---|
| TEPEZZA |
|
$436 | — | — |
| RECORLEV |
|
$242 | — | — |
| AFREZZA |
|
$215 | — | — |
| RYBELSUS |
|
$170 | 27 | — |
| Ozempic |
|
$170 | 585 | — |
A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.
See all 19 in the dashboard with a free accountRecords
456 reportedEvery payment, record by record
Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.
Other Nurse Practitioner, Primary Care in California
Leslie Fletcher
Nurse Practitioner, Primary Care · Torrance, CA
Hamideh Pourzand
Nurse Practitioner, Primary Care · Los Angeles, CA
Veronica Ramirez
Nurse Practitioner, Primary Care · Sacramento, CA
Tyson Fieldsted
Nurse Practitioner, Primary Care · Bakersfield, CA
Kathryn Cooper
Nurse Practitioner, Primary Care · San Diego, CA
Shalaine Corbilla
Nurse Practitioner, Primary Care · La Mesa, CA
Related records
Nurse Practitioner, Primary Care in California
Practitioners in the same specialty and state, ranked by reported value.
All Nurse Practitioner, Primary Care
Everyone recorded under this specialty, nationwide.
Doctors in California
Every practitioner in the state with a reported payment.
How to read this page
What each amount means, and what it does not mean.
What this means
U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.
An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.
Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.